Metformin improves chronic rhinosinusitis with depressive-like behavior in mice by targeting TCF4 to inhibit the TLR4/NF-κB pathway
Abstract
Chronic rhinosinusitis (CRS) frequently co-occurs with depressive disorders. TCF4 aberrant expression is strongly linked to CRS with depression-like behaviors (CRSDB), highlighting the urgent need for TCF4-targeted drugs to treat this complex comorbidity. This study validated the reproducibility and stability of the previously developed mouse model of CRSDB by assessing nasal and hippocampal histopathology via H&E, PAS, and Nissl staining. ELISA determined inflammatory cytokine levels. TCF4's role was explored through lentivirus-mediated in vivo and in vitro microglial knockdown. TLR4/NF-κB pathway regulation by TCF4 was confirmed via immunofluorescence, Western Blot, and RT-qPCR. Metformin's therapeutic effect was tested, with its TCF4 targeting verified by molecular docking and in vitro experiments. The study comprehensively links TCF4 to neuroinflammation in CRSDB, highlighting metformin's potential as a therapeutic agent. The CRSDB model exhibited excellent reproducibility and time-dependent exacerbation of depression-like behaviors, cognitive deficits, and concurrent nasal and hippocampal inflammation. Mechanistically, CRSDB induced TCF4 upregulation, which activated the TLR4/NF-κB signaling pathway, leading to microglial activation and neuroinflammation. Knockdown of TCF4 significantly alleviated behavioral impairments, suppressed microglial activation, and mitigated peripheral inflammation. Furthermore, We identified TCF4 as a direct target of metformin, through which…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.